



# TÜRKİYE

## Pharmaceutical pricing and reimbursement policies 2024

İrem Karaömerlioğlu<sup>1</sup>, Pharm, PhD [irem.karaomerlioglu@gmail.com](mailto:irem.karaomerlioglu@gmail.com)

<sup>1</sup>Turkish Medicines and Medical Devices Agency

### TMMDA Turkish Medicines and Medical Devices Agency

Ministry of Health, +90 312 218 3000 <https://www.titck.gov.tr/>

Marketing Authorization | Clinical Trials | Quality Assurance | Inspection & Surveillance | Analysis & Control | Pharmacovigilance | Pricing (ex-factory, wholesale and retail prices) | Health Technology Assessment | Member of the Reimbursement Commissions

### SSI Social Security Institution

Ministry of Labour and Social Security, +90 312 207 8000 [gssqm@sgk.gov.tr](mailto:gssqm@sgk.gov.tr)

Reimbursement | Pricing (public prices) | Health Technology Assessment | Member of the Price Assessment Commission

## Pricing of medicines

### TMMDA statutory pricing in & outpatient sector

*Regulation of ex-factory, wholesale and retail prices of pharmaceuticals*

**Reference pricing system (RPS)** since 2004  
**External RP**

- Imported & local innovator medicines
- Imported generics
- Lowest ex-factory price
- Reference countries (France, Greece, Italy, Portugal and Spain) or import/EU/other countries.

**Internal RP:** Local generic medicines

**Remuneration** applied regressively to wholesale and retail (pharmacy) prices

**Tendering** in the inpatient/ hospital care sector

**Reference Price (RP) set at**

**60%** Innovator medicine w/generic

**80%** Price-protected products are those containing an active ingredient launched before 01/08/1987.


**100%** Biosimilar

**10%** VAT

**0%** Import fee

### Price Assessment Commission (PAC)

- Determination of the RP exchange rate (EUR to TRY) (set at **60%** of the average euro value from the previous year.)
- Price changes to prevent medicine shortages.



## Coverage / Reimbursement

### SSI coverage/reimbursement

*(Including outpatient and inpatient; public institutions and private institutions w/additional payment)*

- Compulsory health insurance, financed by premiums.
- **98%** of the population is covered by the national health system.
- **8399** medicines in the positive list
- **387** medicines covered under the Named Patient Program

**Public (reimbursement) price**

**Internal RPS;** ATC-5 (active substance) since 2005

**0% to 41%** discount for innovators **28%** max discount for generics

### Co-payments

**10%** of the cost of medicines for pensioners and their dependants.


**20%** of the cost of medicines for other insured persons and their dependants.

### Prescription fees

3 TRY for up to 3 prescribed boxes plus 1 TRY for each additional box.

**Exemptions** for vulnerable groups, those with chronic diseases (e.g. cardiovascular disease, cancer, diabetes or rare diseases) and inpatients.

### Healthcare Services Pricing Commission Reimbursement Commissions



### National governmental disease program (Ministry of Health)

#### Vaccinations

Childhood vaccinations BCG,  
Hepatitis B, Pneumococcal disease,  
Meningitis, Influenza,  
Meningococcal disease, Tetanus-diphtheria,  
Covid 19.

## HTA

\*HTA is not applied in pricing, only in [reimbursement processes](#). **3** HTA committees. **No** independent HTA body.

**SSI** Decision making. **TMMDA** Advisory opinions.

**Department of Research, Development and Health Technology Assessment (Ministry of Health)** Publishes [national reports](#) on various health issues and health technologies.